Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 15Venous Thrombosis 11Pulmonary Embolism 10Neoplasms 9Thrombosis 4Thromboembolism 4Pancreatic Neoplasms 4Lung Neoplasms 4Multiple Myeloma 3Neoplasm Metastasis 2Lymphoma 2Hemorrhage 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Thrombophilia 1Thrombocytopenia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Ovarian Neoplasms 1Obesity 1Neoplasms, Plasma Cell 1

Interventions

apixaban 1Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mesenteric Ischemia × Dalteparin × Clear all
NCT02585713 2020-08-04

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Academic and Community Cancer Research United

Phase 3 Completed
300 enrolled 11 charts
Classical hematology

Neoplasm Metastasis, Neoplasms, Pulmonary Embolism, Venous Thrombosis, Intracranial Thrombosis, Venous Thromboembolism, Mesenteric Ischemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡